Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2005
06/15/2005EP1539149A2 Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression
06/15/2005EP1539148A2 Bicifadine formulation
06/15/2005EP1539147A1 Methods of treating microbial infections in humans and animals
06/15/2005EP1539146A1 Dispersible tablets for oral administration
06/15/2005EP1539145A2 Method of treating tremors
06/15/2005EP1539144A2 Multistage formulation containing a biguanide and a thiazolidinedione derivative
06/15/2005EP1539143A2 Leflunomide analogs for treating rheumatoid arthritis
06/15/2005EP1539142A2 Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer s disease
06/15/2005EP1539140A1 Carvedilol hydobromide
06/15/2005EP1539139A2 Compositions and methods for separating amines and amino acids from their counter-enantiomers
06/15/2005EP1539138A1 Therapeutic process for the treatment of obesity and associated metabolic disorders
06/15/2005EP1539137A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
06/15/2005EP1539136A2 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders
06/15/2005EP1539135A1 Treatment of dyskinesia
06/15/2005EP1539134A2 Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
06/15/2005EP1539133A1 Aminocyclohexene quinolines and their azaisosteric analogues with antibacterial activity
06/15/2005EP1539132A1 Use of 2,3 alkylcarbonyloxybenzoic acids, derivatives and analogues therefrom in the treatment of tissue and cellular dysfunction damage and injury in mammals
06/15/2005EP1539131A2 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
06/15/2005EP1539130A1 Percutaneous and perungual delivery system
06/15/2005EP1539129A1 Dosage forms and related therapies
06/15/2005EP1539128A2 Use of skin-protecting substances
06/15/2005EP1539127A1 Method of treating osteoarthritis
06/15/2005EP1539126A1 Pharmaceutical formulations of modafinil
06/15/2005EP1539125A1 A composition comprising phytospingosine derivatives for apoptosis induction
06/15/2005EP1539124A2 Compositions and kits for the removal of irritating compounds from bodily surfaces
06/15/2005EP1539123A1 Use of a combination of dppe with other chemotherapeutic agents for the treatment of breast cancer
06/15/2005EP1539122A2 Aqueous 2,6-diisopropylphenol pharmaceutical compositions
06/15/2005EP1539121A2 Methods of promoting osteogenesis
06/15/2005EP1539120A1 Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea
06/15/2005EP1539119A1 Palatable controlled-release formulation for companion animals
06/15/2005EP1539117A1 Formulations of fenofibrate and/or fenofibrate derivatives with improved oral bioavailability
06/15/2005EP1539115A1 Methods and dosage forms for controlled delivery of paliperidone
06/15/2005EP1539113A2 Modified release ketoprofen dosage form
06/15/2005EP1539111A1 Oral dosage forms of water insoluble drugs and methods of making the same
06/15/2005EP1539109A1 Block copolymer micelle composition having an enhanced drug-loading capacity and sustained release
06/15/2005EP1539108A1 Vesicle-encapsulated corticosteroids for the treatment of cancer
06/15/2005EP1539107A2 Buccal, polar and non-polar spray or capsule containing drugs for treating pain
06/15/2005EP1539106A2 Buccal polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
06/15/2005EP1539103A2 Methods of treating idiopathic pulmonary fibrosis
06/15/2005EP1539102A2 Pharmaceutically active lipid based formulation of sn38
06/15/2005EP1539097A1 Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
06/15/2005EP1539096A1 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
06/15/2005EP1539095A1 Preventing or treating epithelial tissue damage or hair loss
06/15/2005EP1539088A1 Hair treatment agent containing an active combination of liposomes
06/15/2005EP1539084A1 Composition and method for treating soft nails
06/15/2005EP1539069A1 Transmucosal delivery of cannabinoids
06/15/2005EP1539041A1 Devices delivering therapeutic agents and methods regarding the same
06/15/2005EP1539023A2 Treatment of multiple sclerosis with brain targeted anti oxidant compounds
06/15/2005EP1538980A1 Devices and methodologies useful in body aesthetics
06/15/2005EP1538908A2 Novel substituted benzimidazole dosage forms and method of using same
06/15/2005EP1538907A2 Inhibitors of ftsz and uses thereof
06/15/2005EP1538904A2 Immunostimulatory nucleic acids
06/15/2005EP1538903A2 Method of treating diabetes and related conditions
06/15/2005EP1474154B1 Improvements in or relating to compositions
06/15/2005EP1450808B1 Quinazoline derivatives for the treatment of t cell mediated diseases
06/15/2005EP1448560B1 3-SUBSTITUTED OXINDOLE beta 3 AGONISTS
06/15/2005EP1439831B1 Pharmaco-dietary preparation having a nutrition-supplementing and nutrition-enhancing effect
06/15/2005EP1435937B1 Composition comprising paracetamol and a bitterness masking component
06/15/2005EP1419163B1 Tricyclic imidazopyridines
06/15/2005EP1411911A4 Beta-adrenergic blockade reversal of catabolism after severe burn
06/15/2005EP1408977B1 A combination therapy for the treatment of heart failure
06/15/2005EP1373240B1 Retinoid x receptor modulators
06/15/2005EP1372669B1 Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
06/15/2005EP1368337B1 Piperazine derivatives and their use as 5-ht1b ligands
06/15/2005EP1359816B1 Combination of probiotics
06/15/2005EP1351680B1 Use of anethole-dithiolethione for preventing and treating drug-induced tendon toxicity
06/15/2005EP1349856B1 Isoindolin-1-one glucokinase activators
06/15/2005EP1345609B1 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists
06/15/2005EP1341764B1 Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
06/15/2005EP1334108B1 ARYL PHOSPHATE DERIVATIVES OF d4T
06/15/2005EP1326866B1 Substituted 3.4-dihydro-pyrido[1,2-a]pyrimidines
06/15/2005EP1325007B1 Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
06/15/2005EP1311504B1 Tetrazolyl-phenyl acetamide glucokinase activators
06/15/2005EP1311259B1 Pharmaceutical composition comprising an ester of 5-aminolevulinic acid as photochemotherapeutic agent and a mucoadhesive agent
06/15/2005EP1305301B1 Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
06/15/2005EP1299107B1 Highly concentrated stable meloxicam solutions
06/15/2005EP1289916A4 Purification of xanthophylls from marigold extracts that contain high levels of chlorophylls
06/15/2005EP1278740B1 Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
06/15/2005EP1276496B1 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
06/15/2005EP1268519B1 Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
06/15/2005EP1261345B1 Herbal supplement for cognitive related impairment due to estrogen loss
06/15/2005EP1259261B1 Pharmaceutical compositions comprising terbinafine
06/15/2005EP1259229B1 USE OF BENZO-THIENO[2,3-d]PYRIMIDINES HAVING PDE V INHIBITING ACTIVITY FOR THE TREATMENT OF ERECTILE DYSFUNCTION
06/15/2005EP1257277B1 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
06/15/2005EP1256576B1 Fused imidazolium derivatives
06/15/2005EP1251856B1 Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devices
06/15/2005EP1251841B1 Camphor aqueous solution for treating degenerative or autoimmune diseases and as immunomodulatory agent
06/15/2005EP1248785B1 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
06/15/2005EP1248610B1 Use of at least a fatty ester for preparing a composition for the therapeutic and/or cosmetic treatment of prostatic hypertrophy, prostatic adenocarcinoma, acne, hyperseborrhea, alopecia and hirsutism
06/15/2005EP1244625B1 4-pyridinyl-n-acyl-l-phenylalanines
06/15/2005EP1232139B1 Nervonic acid derivatives, their preparation and use
06/15/2005EP1222194B1 7-acylamino-3-heteroarylthio-3-cephem carboxylic acid antibiotics and prodrugs thereof
06/15/2005EP1174134B1 Melatonin for treating paralysis caused by cerebral infarction
06/15/2005EP1171121B1 Pharmaceutical compositions comprising dipeptidylpeptidase iv inhibitors for the promotion of growth
06/15/2005EP1165070B1 Thiadiazolyl urea or thiourea derivatives for antiviral treatment
06/15/2005EP1150973B1 Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
06/15/2005EP1140915B1 4-(aminomethyl)-piperidine benzamides for treating gastrointestinal disorders
06/15/2005EP1134219B1 Cycloalkyl-substituted aminomethylpyrrolidine derivatives
06/15/2005EP1126843A4 Compounds derived from an amine nucleus that are inhibitors of impdh enzyme
06/15/2005EP1114031B1 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors
1 ... 4654 4655 4656 4657 4658 4659 4660 4661 4662 4663 4664 4665 4666 4667 4668 4669 4670 4671 4672 4673 4674 ... 7860